Lecanemab-Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. (PubMed, J Pharm Technol) - Oct 18, 2026 - "However, its clinical benefit must be weighed against ARIA risk and substantial financial burden. Current evidence supports its use in carefully selected patients with early AD under close supervision."
Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia
|
|
Bao Anh Tran; Carol Fox; Jasmine Cutler; Krystal Bullers
|